EVIDENCE BRIEF

Duration of Antibiotic Treatment for Uncomplicated Cellulitis in Long-Term Care Residents

October 2018

Key Messages

- Recent evidence suggests that short courses of antibiotics (5-7 days) are appropriate for residents with cellulitis that are responding to therapy by day five with no deep-seated infection.

- There are several advantages to short course antibiotic therapy when compared to longer durations, including less side effects,\(^1,2\) less risk of antibiotic-resistant organisms\(^3,4\) and less risk of \textit{C. difficile} infection.\(^5\)
**Issue and Research Question**

Overuse of antimicrobial therapy in the long-term care (LTC) setting is common and leads to patient harm.⁶ Seventy eight (78) % of Ontario LTC residents will receive at least one course of antimicrobial therapy over the course of a year. Skin infections are one of the most common indications for antibiotic therapy in the LTC setting. Approximately 13% of antibiotic courses are prescribed for skin and soft tissue infections, the most common of which is cellulitis.⁷

Sixty three (63) % of prescribed courses of antibiotic treatment in LTC are longer than 10 days. Duration of therapy varies drastically based on prescriber, but not patient characteristics.⁸ This data suggests that habit and experience play a large role in antibiotic prescribing patterns in long-term care. Prolonged treatment specifically for skin infections is common. A study in hospitalized patients found that the average length of therapy was 13 days (IQR 10-14 days).⁹ Excessive durations of antibiotics are often prescribed for cellulitis because the clinical signs of inflammation (such as redness, swelling and discomfort) persist long after the causative bacteria have been eradicated.

Uncertainty exists regarding the appropriate management of uncomplicated cellulitis in residents of LTC homes, particularly with respect to the appropriate duration of therapy. This document will summarize the literature pertaining to treatment duration for uncomplicated cellulitis, particularly as it relates to residents of LTC homes.

**Methods**

An initial Cochrane Database search was performed to determine if there were any relevant systematic reviews or guidelines pertaining to duration of therapy for uncomplicated cellulitis, particularly in older individuals. Following this, a full primary literature search was performed. On April 11, 2017, Public Health Ontario (PHO) Library Services performed a literature search of articles published since 2004 using three databases (MEDLINE, Embase, CINAHL). The search included the concepts “cellulitis,” “antibiotic” and “duration.” Both primary literature and review articles were searched to comprehensively capture all relevant literature. English-language articles retrieved by the searches were assessed for eligibility by PHO staff. Articles were included if they were interventional studies comparing short course (<7 days) to longer courses (≥ 7 days) for treatment of cellulitis. Studies were included if different agents were used in each treatment arm; however, single dose treatment studies were excluded.
Main Findings

The initial literature search for articles published since 2004 retrieved 2248 references. After title and abstract screening, three eligible studies were found on this topic. No systematic reviews were found on this topic.

**Short course antibiotic therapy (5-7 days) results in similar outcomes compared to long durations (10 days) for uncomplicated cellulitis.**

Of the three studies, a total of 1,420 patients with acute skin infections were included. Studies were all randomized controlled trials, two of which used non-inferiority designs. Short course therapy ranged from 5 to 6 days, whereas longer course therapy was 10 days in each study. One study used the same drug (levofloxacin) in both long and short course groups, whereas the other two used a different medication within the same class (tedizolid in short course, linezolid in long course group).

No studies focused on long-term care residents specifically; however, a number of cellulitis patients were hospitalized; 13% in Hepburn et al., 42% in Moran et al., not reported in Prokocimer et al. The mean age range was 43 to 52 years of age. One study allowed for short course if patients had at least minimal improvement by day five of therapy, whereas the others were fixed courses of treatment regardless of symptom improvement.

All studies found no difference in clinical outcomes between short and long course therapy. Outcomes included resolution of infection both early in therapy and after completion of the treatment course. No differences in overall rates of adverse events were reported between study groups.

Appendix A is a table summarizing all studies comparing short course (less than 7 days) to long course (7-14 days) of antibiotics for treatment of uncomplicated cellulitis.

Discussion and Conclusions

Data from adult patients with cellulitis indicate that short courses of antibiotics (5-6 days) have similar efficacy to longer courses (10 days) in terms of clinical cure of infection. These studies included both outpatient and inpatients.

Limitations of this data include:

- Lack of data in older adults
- No studies in LTC setting
- Antibiotic agents used are not currently recommended for first line therapy for cellulitis
Older adults are at increased risk of infections, including those involving the skin. This is in part due to reduced immunocompetence, thinning of the skin and reduced blood flow. Additionally, cognitive factors may result in delayed reporting and recognition of skin infections.

On the other hand, given the lack of data to support prolonged duration of therapy for cellulitis, in addition to the paucibacillary nature of these infections, short course treatment is desirable for all patients with uncomplicated infection including older residents of LTC homes. A short course is reasonable in patients who have initially responded to infection by day five, have no un-drained collection or lesion requiring debridement, no deep-seated infection and adequate circulation at the site of infection.

There are several risks to prolonged courses of antimicrobial therapy. Due to physiological changes associated with aging, older adults are more susceptible to the negative consequences of antibiotics, including adverse effects and drug interactions. Prolonged antimicrobial therapy has been shown in many studies to result in a greater risk of acquiring antibiotic resistant organisms. Additionally, longer durations of antimicrobial therapy are associated with increased risk of \textit{C. difficile} infection (CDI). Older adults are already more susceptible to CDI and more likely to suffer morbidity and mortality from this infection.

Given the lack of proven efficacy with longer courses, in combination with the risks associated with prolonged antibiotic therapy, short course treatment should be used whenever possible for management of uncomplicated cellulitis in LTC home residents.
## Appendix A: Studies Comparing Duration of Antibiotic Therapy for Uncomplicated Cellulitis

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Patients</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepburn, 2004¹⁰</td>
<td>Randomized Double blind</td>
<td>Uncomplicated cellulitis, presenting to emergency department or a or</td>
<td>5 days treatment: Complete 5 days of antibiotic therapy with levofloxacin 500</td>
<td>10 days treatment: Complete 5 days of antibiotic therapy with levofloxacin 500</td>
<td>Resolution of infection (at day 14) with no symptom recurrence (at day</td>
</tr>
<tr>
<td></td>
<td>Single-center ITT,</td>
<td>ambulatory clinic in adults (13% hospitalized)</td>
<td>mg PO daily</td>
<td>mg PO daily</td>
<td>28): 5 days: 98% 10 days: 98% P&gt;0.05</td>
</tr>
<tr>
<td></td>
<td>superiority analysis</td>
<td>(with at least minimal improvement by 5 days of therapy)</td>
<td>Plus placebo for an additional 5 days</td>
<td>Plus levofloxacin for an additional 5 days</td>
<td>No serious adverse events reported</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n=87 randomized</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>mean age = 52.5 y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prokocimer, 2013</td>
<td>Randomized Double blind</td>
<td>Acute bacterial skin and skin structure infections in adults (complicated:</td>
<td>Tedizolid 200 mg PO once daily x 6 days</td>
<td>Linezolid 600 mg PO bid x 10 days</td>
<td>Early clinical response (48-72h): Tedizolid: 79.5% Linezolid: 79.4%</td>
</tr>
<tr>
<td>ESTABLISH-1¹¹</td>
<td>Multi-center ITT,</td>
<td>at least 1 local and 1 regional or systemic manifestation). Gram positive</td>
<td></td>
<td></td>
<td>Treatment difference 0.1% [95% CI, -6.1% to 6.2%])</td>
</tr>
<tr>
<td></td>
<td>Non-inferiority</td>
<td>infection suspected or documented.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(margin=10%) analysis</td>
<td></td>
<td></td>
<td></td>
<td>Sustained clinical response (day 11): Tedizolid: 69.3% Linezolid: 71.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Treatment difference -2.6% [95% CI, -9.6% to 4.2%])</td>
</tr>
</tbody>
</table>
### Moran G, 2014
**ESTABLISH-2**

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Patients</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Randomized Double blind Multi-center ITT, Non-inferiority (margin=10%) analysis</td>
<td>n=667 randomized mean age = 43.3 y</td>
<td>Tedizolid 200 mg daily x 6 days IV → PO Switch if clinical improvement and afebrile</td>
<td>Linezolid 600 mg BID x 10 days IV → PO Switch if clinical improvement and afebrile</td>
<td>Adverse events: Tedizolid: 40.8% Linezolid: 43.3% No statistically significant difference</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patients ≥ 12 years with acute bacterial skin and skin structure infections Minimum lesion area 75 cm² and suspected or documented gram positive pathogen (42.5% hospitalized) n=666 randomized mean age = 46 y</td>
<td></td>
<td></td>
<td>Early clinical response (48-72h): Tedizolid: 85% Linezolid: 83% Treatment difference 2.6% [95% CI, -3.0% to 8.2%]) End of treatment response: Tedizolid: 87% Linezolid: 88% Treatment difference -1.0% [95% CI, -6.1% to 4.1%]) Adverse events: Tedizolid: 45% Linezolid: 43% No statistically significant difference</td>
</tr>
</tbody>
</table>
Specifications and Limitations of Evidence Brief

The purpose of this Evidence Brief is to investigate a research question in a timely manner to help inform decision making. The Evidence Brief presents key findings, based on a systematic search of the best available evidence near the time of publication, as well as systematic screening and extraction of the data from that evidence. It does not report the same level of detail as a full systematic review. Every attempt has been made to incorporate the highest level of evidence on the topic. There may be relevant individual studies that are not included; however, it is important to consider at the time of use of this brief whether individual studies would alter the conclusions drawn from the document.

Additional Resources

- [Duration of Antibiotic Treatment for Pneumonia in Long-Term Care Residents](Evidence Brief)
- [Shorter is Smarter: Reducing Duration of Antibiotic Treatment for Common Infections in Long-Term Care](Fact Sheet)
- [Shorter is Smarter: Reduce Duration of Antibiotic Therapy in Long-Term Care](Infographic)
- [Duration of Antibiotic Treatment for Uncomplicated Urinary Tract Infection in Long-Term Care Residents](Evidence Brief)
References


10. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern
Duration of antibiotic treatment for uncomplicated cellulitis in long-term care residents

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/760487

https://jamanetwork.com/journals/jama/fullarticle/1570280


https://academic.oup.com/cid/article/40/7/997/373878

https://academic.oup.com/cid/article/50/2/194/328758
Author

Contributors
Rita Ha, Antimicrobial Stewardship Pharmacist Consultant, Infection Prevention and Control, Public Health Ontario
Nick Daneman, Physician and Scientist, Infection Prevention and Control, Public Health Ontario
Kevin Schwartz, Physician and Scientist, Infection Prevention and Control, Public Health Ontario

Reviewers
Dan Dalton, Pharmacist, Medical Pharmacies Group Ltd.
Carrie Heer, Nurse Practitioner, St. Joseph’s Health Centre, Guelph
Justin Lin, Pharmacist, Medical Pharmacies Group Ltd.
Heidi Wittke, Director, Clinical, Medisystems Pharmacy
Louis Kennedy, Hospitalist, Providence Care Hospital, Medical Director, Arbour Heights LTC
Allan Grill, Lead Physician, Markham Family Health Team

Citation

ISBN: 978-1-4868-2514-1

©Queen’s Printer for Ontario, 2018

Disclaimer
This document was developed by Public Health Ontario (PHO). PHO provides scientific and technical advice to Ontario’s government, public health organizations and health care providers. PHO’s work is guided by the current best available evidence at the time of publication.

The application and use of this document is the responsibility of the user. PHO assumes no liability resulting from any such application or use.

This document may be reproduced without permission for non-commercial purposes only and provided that appropriate credit is given to PHO. No changes and/or modifications may be made to this document without express written permission from PHO.
For Further Information
Antimicrobial Stewardship Program, Infection Prevention and Control
Email: ASP@oahpp.ca

Public Health Ontario
Public Health Ontario is a Crown corporation dedicated to protecting and promoting the health of all Ontarians and reducing inequities in health. Public Health Ontario links public health practitioners, front-line health workers and researchers to the best scientific intelligence and knowledge from around the world.

For more information about PHO, visit publichealthontario.ca.

Public Health Ontario acknowledges the financial support of the Ontario Government.